Improvement of affinity and potency of a monoclonal antibody against Shigella flexneri 3a O-antigen via phage display and whole-cell in-solution panning
Xerri, N. L.; Pulido, S.; Kedzior, M.; Savarino, P.; Williams, T.; Gallant, R. M.; Kaminski, R. W.; Sok, D.; Schmidt, H. R.
Show abstract
As rates of antimicrobial resistance (AMR) among bacterial pathogens continue to rise, the discovery and development of novel classes of therapeutics that can serve as alternatives or adjuncts to traditional small-molecule antibiotics, such as monoclonal antibodies (mAbs), is a public health priority. Some of the most promising antigen targets for antibacterial mAbs are surface polysaccharides such as O-antigen (O-Ag), a component of the lipopolysaccharide found on the outer membrane of gram-negative bacteria. However, developing mAbs against bacterial surface polysaccharides with sufficient breadth and potency to be clinically viable is difficult in part because antibodies against polysaccharides are generally low affinity, and the challenging biochemistry of polysaccharides often precludes further affinity maturation of mAbs against these targets in vitro. Here, we use a phage display library and a whole-cell in-solution panning strategy to successfully improve the affinity of a mAb against Shigella flexneri 3a O-Ag in vitro without requiring the purification of the target antigen. We demonstrate that a single mutation can improve apparent affinity approximately 10-fold without detectably increasing polyreactivity, and increased affinity correlates with enhanced potency in antibacterial effector function and anti-virulence assays. In addition, the most potent variants also gained increased breadth, successfully coordinating complement deposition and complement-independent opsonophagocytosis against S. flexneri 3b, a serotype weakly recognized by the parent mAb. Altogether, this work represents an important first step towards expanding the antibody engineering toolkit for bacterial surface polysaccharides, which will aid the development of novel mAb therapeutics against AMR bacterial pathogens.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition 94%
- Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination 94%
- ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants 94%
Similar papers in this journal
- Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages 95%
- Memory B cell Development in Response to mRNA SARS-CoV-2 and Nanoparticle Immunization in Mice 95%
- Lipoproteome screening of the Lyme disease agent identifies novel inhibitors of antibody-mediated complement killing 95%
Similar papers in this journal
- A Broadly Neutralizing Macaque Monoclonal Antibody Against the HIV-1 V3-Glycan Patch 95%
- Amidase and Lysozyme Dual Functions in TseP Reveal a New Family of Chimeric Effectors in the Type VI Secretion System 95%
- Structural basis of malaria transmission blockade by a monoclonal antibody to gamete fusogen HAP2 95%
Similar papers in this journal
- Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum 95%
- Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies 95%
- Development Of A Potent Monoclonal Antibody For Treatment Of Human Metapneumovirus Infections 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.